Oruka Therapeutics, Inc. (ORKA)
Nasdaq · Healthcare · Biotechnology
$84.38−0.17%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $5.6B
- 52-week range
- $19.89 – $115.52
- 52-week change
- +310.89%
- EPS (trailing)
- −$2.04
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Net income
- −$105M
- Free cash flow
- −$88.4M
From the company’s annual report on SEC EDGAR.
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Headquarters: Menlo Park, United States · 68 employees · orukatx.com